Armata Pharmaceuticals, Inc. Share Price

Equities

ARMP

US04216R1023

Biotechnology & Medical Research

Market Closed - Nyse 01:30:00 01/06/2024 am IST 5-day change 1st Jan Change
2.72 USD +0.74% Intraday chart for Armata Pharmaceuticals, Inc. +3.82% -16.05%
Sales 2024 * 45.38L 38Cr Sales 2025 * 27.5L 23Cr Capitalization 9.83Cr 820.28Cr
Net income 2024 * -7.2Cr -600.57Cr Net income 2025 * -6.7Cr -558.86Cr EV / Sales 2024 * 21.7 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 35.8 x
P/E ratio 2024 *
-1.43 x
P/E ratio 2025 *
-2.09 x
Employees 66
Yield 2024 *
-
Yield 2025 *
-
Free-Float 29.72%
More Fundamentals * Assessed data
Dynamic Chart
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000 MT
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference CI
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus CI
Armata Pharmaceuticals, Inc. Announces CFO Changes CI
Armata Pharmaceuticals, Inc. Announces Executive Changes CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Armata Pharmaceuticals, Inc. Announces That It Has Entered into A Credit and Security Agreement with Innoviva Strategic Opportunities Llc CI
Armata Pharmaceuticals, Inc. Announces Executive Changes CI
Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors CI
More news
1 day+0.74%
1 week+3.82%
1 month+6.67%
3 months-30.96%
6 months+24.20%
Current year-16.05%
More quotes
1 week
2.53
Extreme 2.53
3.22
1 month
2.30
Extreme 2.3
3.45
Current year
2.26
Extreme 2.26
4.48
1 year
1.07
Extreme 1.0701
5.26
3 years
0.83
Extreme 0.8311
6.49
5 years
0.83
Extreme 0.8311
10.48
10 years
0.83
Extreme 0.8311
10.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 11/23/11
Chief Tech/Sci/R&D Officer - 26/20/26
Corporate Officer/Principal - -
Members of the board TitleAgeSince
Director/Board Member 64 12/20/12
Director/Board Member 60 09/19/09
Director/Board Member 73 01/21/01
More insiders
Date Price Change Volume
31/24/31 2.72 +0.74% 5,549
30/24/30 2.7 +3.85% 17,379
29/24/29 2.6 -1.14% 4,410
28/24/28 2.63 +0.38% 11,344
24/24/24 2.62 +0.77% 5,309

Delayed Quote Nyse, May 01, 2024 at 01:30 am IST

More quotes
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.72 USD
Average target price
8 USD
Spread / Average Target
+194.12%
Consensus